Lessons from the avandia controversy

被引：8

作者：

Misbin, Robert I. ^{[1
]}

机构：

[1] US FDA, Div Endocrinol & Metab, Silver Spring, MD USA

来源：

DIABETES CARE | 2007年 / 30卷 / 12期

关键词：

D O I：

10.2337/dc07-1908

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3141 / 3144

页数：4

共 26 条

[1]

[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004

[2] The Avandia debate [J].

Bloomgarden, Zachary T. .

DIABETES CARE, 2007, 30 (09) :2401-2408

[3] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494

[4]

*COMM OV GOV REF, 2007, HEAR FDAS ROL EV SAF

[5] Commentary: The PROactive study - The glass is half full [J].

Fonseca, V ;

Jawa, A ;

Asnani, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :25-27

[6]

*FOOD DRUG ADM, 1999, MED OFF REV AV

[7]

*FOOD DRUG ADM, 2007, MED OFF REV ACT

[8]

GOLDEN J, 2005, FOOD DRUG ADM MET EN

[9] Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies [J].

Hanefeld, M ;

Cagatay, M ;

Petrowitsch, T ;

Neuser, D ;

Petzinna, D ;

Rupp, M .

EUROPEAN HEART JOURNAL, 2004, 25 (01) :10-16

[10] Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [J].

Kahn, Steven E. ;

Haffner, Steven M. ;

Heise, Mark A. ;

Herman, William H. ;

Holman, Rury R. ;

Jones, Nigel P. ;

Kravitz, Barbara G. ;

Lachin, John M. ;

O'Neill, M. Colleen ;

Zinman, Bernard ;

Viberti, Giancarlo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2427-2443

← 1 2 3 →